Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 4, 1998, Pages 1168-1172

  Szczeklik, Andrzej ^b   Dworski, Ryszard ^a   Mastalerz, Lucyna ^b   Prokop, Anna ^b   Sheller, James R ^b   Nizankowska, Ewa ^b   Ćmiel, Adam ^b   Oates, John A ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG METABOLITE; LEUKOTRIENE E4; LONG ACTING DRUG; LYSINE ACETYLSALICYLATE; PEPTIDOLEUKOTRIENE; PLACEBO; PROSTAGLANDIN D2; SALMETEROL; SALMETEROL XINAFOATE; SODIUM CHLORIDE;

ADULT; AEROSOL; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; ICOSANOID METABOLISM; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; MEDIATOR RELEASE; NEBULIZATION; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; URINE LEVEL;

EID: 0031739629     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.4.9710043     Document Type: Article

References (32)

1. Samter, M., and R. F. Beers. 1968. Intolerance to aspirin: clinical studies and consideration of its pathogencsis. Ann. Int. Med. 68:975-483.
2. Szczeklik, A., R. J. Gryglewski, and G. Czerniawska-Mysik. 1977. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J. Allergy Clin. Immunol. 60:276-284.
3. Stevenson, D. D. 1984. Diagnosis, prevention and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J. Allergy Clin. Immunol. 74:617-622.
4. Szczeklik, A. 1997. Mechanism of aspirin-induced asthma. Allergy 52: 613-619.
5. Szczeklik, A., R. J. Gryglewski, and G. Czerniawska-Mysik. 1975. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. B.M.J. 1:67-69.
6. Picado, C., J. A. Castillo, J. M. Montserrat, and A. Augusti-Vidal. 1989. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur. Respir. J. 2:127-129.
7. Marquette, C. H., F. Saulnier, O. Leroy, B. Wallaert, C. Chopin, J. M. Demarcq, A. Durocher, and A. B. Tonnel. 1992. Long-term prognosis for near-fatal asthma: a 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for near-fatal attack of asthma. Am. Rev. Respir. Dis. 146:76-81.
8. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143:1025-1029.
9. Ferreri, N. R., W. C. Howland, D. D. Stevenson, and H. L. Spiegelberg. 1988. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am. Rev. Respir. Dis. 137:847-854.
10. Kowalski, M. L., M. Sliwinska-Kowalska, Y. Igarashi, M. V. White, B. Wojciechowska, P. Brayton, H. Kaulbach, J. Rozniecki, and M. A. Kaliner. 1993. Nasal secretions in response to acetylsalicylic acid. J. Allergy Clin. Immunol. 91:580-598.
11. Szczeklik, A., K. Sladek, R. Dworski, E. Nizankowska, J. Soja, J. R. Sheller, and J. Oates. 1996. Bronchial aspirin challenge causes specific eicosanoid response in aspirin sensitive asthmatics. Am. J. Respir. Crit. Care Med. 154:1608-1614.
12. 4 synthase in bronchial biopses from patients with aspirin-intolerant asthma. J. Clin. Invest. 101: 834-846.
13. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350:1599-1600.
14. Christie, P. E., C. M. Smith, and T. H. Lee. 1991. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am. Rev. Respir. Dis. 144:957-958.
15. Dahlen, B., E. Nizankowska, A. Szczeklik, O. Zetterstrom, G. Bochenek, M. Kumlin, L. Mastalerz, G. Pinis, L. J. Swanson, T. I. Boodhoo, S. Wright, L. M., Dube, and S. E. Dahlen. 1998. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care Med. 157:1187-1194.
16. Szczeklik, A., L. Mastalerz, E. Nizankowska, and A. Cmiel. 1996. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 153:567-571.
17. Nelson, H. S. 1995. β-adrenergic bronchodilators. N. Engl. J. Med. 333: 499-506.
18. Kumlin, M. 1997. Measurements of leukotrienes in urine: strategies and applications. Allergy 52:124-135.
19. 2 after allergen inhalation in atopic asthmatics. Adv. Prostaglanilin Thromboxane Leukot. Res. 21A:433-436.
20. 2 in a normal human male volunteer. J. Biol. Chem. 260:13172-13180.
21. 4 in humans. Clin. Exp. Allergy 25:467-479.
22. 2 by a stable isotope dilution mass spectrometric assay. Anal. Biochem. 193:142-148.
23. Cartwright, G. E. 1968. Diagnostic laboratory hematology, 4th ed. Grune Stratton, New York, 48-50.
24. Peat, J. K., W. R. Unger, and D. Combe. 1994. Measuring changes in logarithmic data, with special reference to bronchial responsiveness. J. Clin. Epidemiol. 47:1099-1108.
25. Bland, J. M., and D. G. Altman. 1986. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1: 307-310.
26. Dahlen, B. 1993. Leukotrienes as Mediators of Asthma Induced by Aspirin and Allergy. Karolinska Institute Publishers, Stockholm.
27. Sladek, K., and A. Szczeklik. 1993. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6:391-399.
28. 2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 98:421-432.
29. 4 excretion. J. Allergy Clin. Immunol. 89:575-583.
30. Butchers, P. R., C. J. Vardey, and M. Johnson. 1991. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br. J. Pharmacol. 104:672-676.
31. 4 by human eosinophils. Eur. Res. J. 22:141s-145s.
32. Murray, J. J., D. D. Hagaman, R. Dworski, B. Keane, and J. R. Sheller. 1998. Inhibition by salmeterol and beclamethasone of late phase response to segmental antigen challenge in asthmatics (abstract). Am. J. Respir. Crit. Care Med. 157:A872.